The Association of Former JW Fulbright Scholars Spain and the International Institute are pleased to invite you to:
“Oncology in the XXI Century: Precision Medicine vs. Immunotherapy”
A lecture by Dr. Mariano Barbacid
Mariano Barbacid: He is AXA-CNIO Professor of Molecular Oncology and head of the Experimental Oncology group at the National Cancer Research Center (CNIO).
He studied Chemical Sciences (specializing in Biochemistry) at the Complutense University, obtaining his doctorate in 1974 after completing his doctoral thesis at the Institute of Cell Biology of the CSIC under the direction of Dr. David Vázquez. Between 1974 and 1977 he completed his postdoctoral training at the Cancer Institute (NCI) in the United States. In 1978 he formed his own research group at the NCI where he worked until 1988. In 1982 he first isolated a mutated human gene capable of causing cancer (oncogene), thus identifying the first molecular alteration involved in tumor development. These discoveries served to establish the molecular bases of cancer and open a new field of research that we now know as Molecular Oncology.
During the following decade (1988-1998) he worked in the pharmaceutical industry, becoming Vice President of Preclinical Oncology at the multinational Bristol-Myers Squibb. In 1998 he returned to Spain to found and direct the National Cancer Research Center (CNIO). Dr. Barbacid left the direction of the CNIO in 2011 to focus exclusively on his lines of research. Under his leadership, the CNIO became in less than a decade one of the best research centers in the world according to the "scientific quality" ranking prepared by Scimago Institutions Rankings among more than 3.000 scientific institutions.
Dr. Barbacid has received numerous awards and distinctions, including his appointment as a Foreign Member of the US Academy of Sciences, an honor held by only five other Spanish researchers. In 2014 he was named a Fellow of the Academy of the American Association for Cancer Research (AACR), the first Spaniard to receive this distinction. He is also a member of EMBO (1996), the European Academy (2004) and the European Academy of Cancer Sciences (2009).
In addition, he has received the title of Doctor Honoris Causa by the Menéndez Pelayo International University (1995), by the University of Cantabria (2011) and by the University of Barcelona (2014). He is an Honorary Member of the Royal National Academy of Pharmacy and has received the Gran Cruz del Dos de Mayo, the highest distinction awarded by the Community of Madrid.
Among the international awards, the Medal Burkitt (Ireland, 2017), the Medal of Honor of the International Cancer Agency of the World Health Organization (France, 2007), the award Charles Rodolphe Brupbach (Switzerland 2005), the award Ipsen of Neuronal Plasticity (Vienna, 1994), the Prize Joseph Steiner (Switzerland, 1988) and the Rhodes Memorial Award from the American Association for Cancer Research (USA 1985). In 2011 he received a Endowed Chair (Permanent Chair) of the AXA Research Fund (Paris). Dr. Barbacid is one of the few European scientists to receive two Advanced Grants from the European Research Council since its establishment in 2008.
Among the national awards, the King Juan Carlos I Award (1984), the I Ramiro Carregal Oncology Research Award (2012), the “V de Vida” Award from the Spanish Association Against Cancer (2012), the “Eladio Viñuela ” for Research in Life Sciences (2013) and the 2015st ASEICA Award (XNUMX).
To date, Dr. Barbacid has published 310 scientific papers including 236 original articles, 32 reviews in impact-rated journals, and 46 book chapters. According to Google Scholar, his publications have been cited more than 61.000 times. Currently, Dr. Barbacid's h-index (Hirsch Factor) is 114.